Trials / Unknown
UnknownNCT02404298
Transcriptome Analysis of the Peripheral Blood in CIDP
Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder of peripheral nerves. Intravenous immunoglobulins (IVIg) are a first line therapy for CIDP. The investigators used a transcriptomic approach to compare the gene expression profiles in the peripheral blood of patients having a CIDP or autoimmune diseases, before and after IVIg treatment, in order to identify their mechanism of action in this condition, to lead to a better understanding of CIDP pathophysiology, and potentially determine factors associated with the response to the treatment.
Detailed description
We study the change of the: * gene profile on transcriptome analysis of peripheral blood * T cell repertory * igG dosage * immunological profile Before IVIG (T1 time) and and 3 weeks after IVIg treatment (T2 time). On a population of patients having: CIDP, autoimmune muscular disease, Clarkson syndrome, or autoimmune diseases. We also search for polymorphism of FCgammareceptor, TKPC et CASP3 genes in CIDP patients
Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Autoimmune Diseases
- Clarkson Syndrome
- Muscular Autoimmune Disorders
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IVIg |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2018-01-01
- Completion
- 2018-09-01
- First posted
- 2015-03-31
- Last updated
- 2018-06-04
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02404298. Inclusion in this directory is not an endorsement.